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Abstract
Designing a molecule with desired properties is one of the biggest challenges in drug de-
velopment, as it requires optimization of chemical compound structures with respect to many
complex properties. To augment the compound design process we introduce Mol-CycleGAN
– a CycleGAN-based model that generates optimized compounds with high structural similar-
ity to the original ones. Namely, given a molecule our model generates a structurally similar
one with an optimized value of the considered property. We evaluate the performance of the
model on selected optimization objectives related to structural properties (presence of halo-
gen groups, number of aromatic rings) and to a physicochemical property (penalized logP).
In the task of optimization of penalized logP of drug-like molecules our model significantly
outperforms previous results.
Introduction
The principal goal of the drug design process is to find new chemical compounds that are able to
modulate the activity of a given target (typically a protein) in a desired way.1 However, finding such
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molecules in the high-dimensional chemical space of all molecules without any prior knowledge
is nearly impossible. In silico methods have been introduced to leverage the existing chemical,
pharmacological and biological knowledge, thus forming a new branch of science - computer-
aided drug design (CADD).2,3 Computer methods are nowadays applied at every stage of drug
design pipelines2 - from the search of new, potentially active compounds,4 through optimization
of their activity and physicochemical profile5 and simulating their scheme of interaction with the
target protein,6 to assisting in planning the synthesis and evaluation of its difficulty.7
The recent advancements in deep learning encouraged its application in CADD.8 The two
main approaches are: virtual screening, that is using discriminative models to screen commercial
databases and classify molecules as likely active or inactive; de novo design, that is using gen-
erative models to propose novel molecules that likely possess the desired properties. The former
application already proved to give outstanding results.9–12 The latter use case is rapidly emerg-
ing, e.g. long short-term memory (LSTM) network architectures have been applied with some
success.13–16
In the center of our interest are the hit-to-lead and lead optimization phases of the compound
design process. Their goals are to optimize the drug-like molecules identified in the previous
steps in terms of the desired activity profile (increased potency towards given target protein and
provision of inactivity towards off-target proteins) and the physicochemical and pharmacokinetic
properties. Optimizing a molecule with respect to multiple properties simultaneously remains a
challenge.5 Nevertheless, some successful approaches to compound generation and optimization
have been proposed.
Variational Autoencoder (VAE)17 can be used for the task of molecule generation. The first
such models18 were based on the SMILES representation. Unfortunately, these models can gen-
erate invalid SMILES that do not correspond to any molecules. Introduction of grammars into the
model improved the success rate of valid SMILES generation.19,20 Maintaining chemical validity
when generating new molecules became possible through VAEs realized directly on molecular
graphs.21,22
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Generative Adversarial Networks (GAN)23 is an alternative architecture that has been ap-
plied to de novo drug design. GANs, together with Reinforcement Learning (RL), were recently
proposed as models that generate molecules with desired properties while promoting diversity.
These models use representations based on SMILES,24 graph adjacency and annotation matrices,25
or are based on graph convolutional policy networks.26 The major obstacle in practical utility of
these approaches is that the generated compounds can be difficult (or even impossible) to synthe-
size.
To address the problem of generating compounds difficult to synthesize, we introduce Mol-
CycleGAN – a generative model based on CycleGAN.27 Given a starting molecule, it generates a
structurally similar one but with a desired characteristics. The similarity between these molecules
is important for two reasons. First, it leads to an easier synthesis of generated molecules, and sec-
ond, such optimization of the selected property is less likely to spoil the previously optimized ones,
which is important in the context of multiparameter optimization. We show that our model gen-
erates molecules that possess desired properties (note that by a molecular property we also mean
binding affinity towards a target protein) while retaining their structural similarity to the starting
compound. Moreover, thanks to employing graph-based representation instead of SMILES, our
algorithm always returns valid compounds.
We evaluate the model’s ability to perform structural transformations and molecular optimiza-
tion. The former indicates that the model is able to do simple structural modifications such as a
change in the presence of halogen groups or number of aromatic rings. In the latter, we aim to
maximize penalized logP to assess the model’s utility for compound design. Penalized logP is
chosen as it is a property often selected as a testing ground for molecule optimization models,22,26
due to its relevance in the drug design process. In the optimization of penalized logP for drug-like
molecules our model significantly outperforms previous results. To the best of our knowledge,
Mol-CycleGAN is the first approach to molecule generation that uses the CycleGAN architecture.
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Methods
Junction Tree Variational Autoencoder
JT-VAE22 (Junction Tree Variational Autoencoder) is a method based on VAE, which works us-
ing graph structures of compounds, in contrast to previous methods which work using the SMILES
representation of molecules.18–20 The VAE models used for molecule generation share the encoder-
decoder architecture. The encoder is a neural network used to calculate a continuous, high-
dimensional representation of a molecule in the so-called latent space, whereas the decoder is
another neural network used to decode a molecule from coordinates in the latent space. In VAEs
the entire encoding-decoding process is stochastic (has a random component). In JT-VAE both the
encoding and decoding algorithms use two components for representing the molecule: a junction-
tree scaffold of molecular sub-components (called clusters) and a molecular graph.22 JT-VAE
shows superior properties compared to SMILES-based VAEs, such as 100% validity of generated
molecules.
Mol-CycleGAN
Mol-CycleGAN is a novel method of performing compound optimization by learning from the sets
of molecules with and without the desired molecular property (denoted by the sets X and Y ). Our
approach is to train a model to perform the transformation G : X Ñ Y and then use this model to
perform optimization of molecules. In the context of compound design X (Y ) can be, e.g., the set
of inactive (active) molecules.
To represent the sets X and Y our approach requires an embedding of molecules which is
reversible, i.e. enables both encoding and decoding of molecules.
For this purpose we use the latent space of JT-VAE, representation created by neural network
during the training process. This approach has the advantage that the distance between molecules
(required to calculate the loss function) can be defined directly in the latent space. Moreover,
molecular properties are easier to express on graphs rather than using linear SMILES representa-
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Figure 1: Schematic diagram of our Mol-CycleGAN. X and Y are the sets of molecules with
selected values of the molecular property (e.g. active/inactive or with high/low values of logP). G
and F are the generators. DX and DY are the discriminators.
tion.28 One could try formulating the CycleGAN model on the SMILES representation directly, but
this would raise the problem of defining a differentiable intermolecular distance, as the standard
manners of measuring similarity between molecules (Tanimoto similarity) are non-differentiable.
Our approach extends the CycleGAN framework27 to molecular embeddings of the latent space
of JT-VAE.22 We represent each molecule as a point in the latent space, given by the mean of the
variational encoding distribution.17 Our model works as follows (Fig. 1): (i) we start by defining
the sets X and Y (e.g., inactive/active molecules); (ii) we introduce the mapping functions G :
X Ñ Y and F : Y Ñ X; (iii) we introduce discriminator DX (and DY ) which force the generator
F (and G) to generate samples from a distribution close to the distribution of X (or Y ). The
components F , G, DX , and DY are modeled by neural networks (see Workflow for technical
details). The main idea of our approach to molecule optimization is to: (i) take the prior molecule
x without a specified feature (e.g. specified number of aromatic rings, water solubility, activity)
from set X , and compute its latent space embedding; (ii) use the generative neural network G to
obtain the embedding of molecule Gpxq, that has this feature (as if the Gpxq molecule came from
set Y ) but is also similar to the original molecule x; (iii) decode the latent space coordinates given
5
by Gpxq to obtain the SMILES representation of the optimized molecule. Thereby, the method is
applicable in lead optimization processes, as the generated compound Gpxq remains structurally
similar to the input molecule.
To train the Mol-CycleGAN we use the following loss function:
LpG,F,DX , DY q “ LGANpG,DY , X, Y q ` LGANpF,DX , Y,Xq
` λ1LcycpG,F q ` λ2LidentitypG,F q,
(1)
and aim to solve
G˚, F ˚ “ argmin
G,F
max
DX ,DY
LpG,F,DX , DY q.
We use the adversarial loss introduced in LS-GAN29:
LGANpG,DY , X, Y q “ 1
2
Ey„pdatapyqrpDY pyq ´ 1q2s `
1
2
Ex„pdatapxqrpDY pGpxqqq2s, (2)
which ensures that the generator G (and F ) generates samples from a distribution close to the
distribution of Y (or X).
The cycle consistency loss
LcycpG,F q “ Ey„pdatapyqr}GpF pyqq ´ y}1s ` Ex„pdatapxqr}F pGpxqq ´ x}1s, (3)
reduces the space of possible mapping functions, such that for a molecule x from set X , the GAN
cycle brings it back to a molecule similar to x, i.e. F pGpxqq is close to x (and analogouslyGpF pyqq
is close to y). The inclusion of the cyclic component acts as a regularization and may also help
in the regime of low data, as the model can learn from both directions of the transformation. This
component makes the resulting model more robust (cf. e.g. the comparison30 of CycleGAN vs
non-cyclic IcGAN31). Finally, to ensure that the generated (optimized) molecule is close to the
starting one we use the identity mapping loss27
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LidentitypG,F q “ Ey„pdatapyqr}F pyq ´ y}1s ` Ex„pdatapxqr}Gpxq ´ x}1s, (4)
which further reduces the space of possible mapping functions and prevents the model from
generating molecules that lay far away from the starting molecule in the latent space of JT-VAE.
In all our experiments we use the hyperparameters λ1 “ 0.3 and λ2 “ 0.1, which were chosen
by checking a couple of combinations (for structural tasks) and verifying that our optimization
process: (i) improves the studied property and (ii) generates molecules similar to the starting ones.
We have not performed a grid search for optimal values of λ1 and λ2, and hence there could be
space for improvement. Note that these parameters control the balance between improvement in
the optimized property and similarity between the generated and the starting molecule. We show in
the Results section that both the improvement and the similarity can be obtained with the proposed
model.
Workflow
We conduct experiments to test whether the proposed model is able to generate molecules that
possess desired properties and are close to the starting molecules. Namely, we evaluate the model
on tasks related to structural modifications, as well as on tasks related to molecule optimization.
For testing molecule optimization we select the octanol-water partition coefficient (logP) penalized
by the synthetic accessibility (SA) score. logP describes lipophilicity - a parameter influencing a
whole set of other characteristics of compounds such as solubility, permeability through biological
membranes, ADME (absorption, distribution, metabolism, and excretion) properties, and toxicity.
We use the formulation as reported in the paper on JT-VAE,22 i.e. for molecule m the penalized
logP is given as logP pmq ´ SApmq. We use the ZINC-250K dataset used in similar studies19,22
which contains 250 000 drug-like molecules extracted from the ZINC database.32 The detailed
formulation of the tasks is the following:
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Algorithm 1 Mol-CycleGAN training algorithm. In all experiments in the paper the following
values are used: α “ 0.0001, λ1 “ 0.3, λ2 “ 0.1, m “ 64.
Require: : α - the learning rate. λ1 - the cycle consistency weight. λ2 - the identity mapping
weight. m, the batch size.
Require: : wX , wY - initial discriminators’ parameters. θG, θF - initial generators’ parameters.
1: Encode the Xtrain, Ytrain with the JT-VAE encoder to obtain the latent space representation of
molecules from the training dataset.
2: while θG, θF have not converged do
3: Sample txpiqumi“1 „ ppXq a batch from the dataset Xtrain.
4: Sample typiqumi“1 „ ppY q a batch from the dataset Ytrain.
5: Calculate the adversarial loss. Ź Eq.(2)
LGAN Ð 12m
řm
i“1
`
DY pypiqq ´ 1
˘2` 1
2m
řm
i“1
`
DY pGpxpiqqq
˘2` 1
2m
řm
i“1
`
DXpxpiqq ´ 1
˘2`
1
2m
řm
i“1
`
DXpF pypiqqq
˘2.
6: Calculate the cycle consistency loss. Ź Eq.(3)
Lcyc Ð 1m
řm
i“1
ˇˇ
F pGpxpiqqq ´ xpiq ˇˇ` 1
m
řm
i“1
ˇˇ
GpF pypiqqq ´ ypiqˇˇ.
7: Calculate the identity mapping loss. Ź Eq.(4)
Lidentity Ð 1m
řm
i“1
ˇˇ
Gpxpiqq ´ xpiqˇˇ` 1
m
řm
i“1
ˇˇ
F pypiqq ´ ypiq ˇˇ.
8: Calculate the loss function. Ź Eq.(1)
LÐ LGAN ` λ1Lcyc ` λ2Lidentity.
9: Calculate the gradients of loss function.
gG Ð ∇θGL; gF Ð ∇θFL.
gX Ð ∇wXL; gY Ð ∇wY L.
10: Minimize the loss function, using the Adam optimizer, with respect to the parameters of
generators G,F .
θG Ð θG ´ α ¨ AdampθG, gGq; θF Ð θF ´ α ¨ AdampθF , gF q.
11: Maximize the loss function, using the Adam optimizer, with respect to the parameters of
discriminators DX , DY .
wX Ð wX ` α ¨ AdampwX , gXq; wY Ð wY ` α ¨ AdampwY , gY q.
12: end while
13: Decode GpXtestq and F pYtestq with the JT-VAE decoder to obtain the SMILES representation
of molecules returned by the Mol-CycleGAN.
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• Structural transformations We test the model’s ability to perform simple structural trans-
formations of the molecules. To this end, we choose the sets X and Y , differing in some
structural aspects, and then test if our model can learn the transformation rules and apply
them to molecules previously unseen by the model. There are two features by which we
divide the sets:
– Halogen moieties We split the dataset into two subsets X and Y . The set Y consists
of molecules which contain at least one of the following SMARTS: ’[!#1]Cl’, ’[!#1]F’,
’[!#1]I’, ’C#N’, whereas the set X consists of such molecules which do not contain
any of them. The SMARTS chosen in this experiment indicate halogen moieties and
the nitrile group. Their presence and position within a molecule can have an immense
impact on the compound’s activity.
– Aromatic rings Molecules in X have exactly two aromatic rings, whereas molecules
in Y have one or three aromatic rings.
• Constrained molecule optimization We optimize penalized logP, while constraining the de-
gree of deviation from the starting molecule. The similarity between molecules is measured
with Tanimoto similarity on Morgan Fingerprints.33 The sets X and Y are random samples
from ZINC-250K, where the compounds’ penalized logP values are below and above the
median, respectively.
• Unconstrained molecule optimization We perform unconstrained optimization of penal-
ized logP. The set X is a random sample from ZINC-250K and the set Y is a random sample
from the top-20% molecules with the highest penalized logP in ZINC-250K.
Composition of the datasets
Dataset sizes In Table 1 we show the number of molecules in the datasets used for training and
testing. In all experiments we use separate sets for training the model (Xtrain and Ytrain) and separate,
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non-overlapping ones for evaluating the model (Xtest and Ytest). In constrained and unconstrained
molecular optimization experiments no Ytest set is required.
Table 1: Dataset sizes
Dataset Halogen Aromatic Constrained Unconstrained
moieties rings optimization optimization
Xtrain 75000 80000 80000 80000
Xtest 86899 18220 800 800
Ytrain 75000 80000 80000 24946
Ytest 12556 43193 - -
Distribution of the selected properties In the experiment on halogen moieties, the setX always
(i.e., both in train- and test-time) contains molecules without halogen moieties, and the set Y
always contains molecules with halogen moieties. In the dataset used to construct the latent space
(ZINC-250K) 65 % molecules do not contain any halogen moiety, whereas the remaining 35 %
contain one or more halogen moieties.
In the experiment on aromatic rings, the setX always (i.e., both in train- and test-time) contains
molecules with 2 rings, and the set Y always contains molecules with 1 or 3 rings. The distribution
of the number of aromatic rings in the dataset used to construct the latent space (ZINC-250K) is
shown in Figure 2 along with the distribution for X and Y .
Figure 2: Number of aromatic rings in ZINC-250K and in the sets used in the experiment on
aromatic rings.
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For the molecule optimization tasks we plot the distribution of the property being optimized
(penalized logP) in Figs. 3 (constrained optimization) and 4 (unconstrained optimization).
Figure 3: Distribution of penalized logP in ZINC-250K and in the sets used in the task of con-
strained molecule optimization. Note that the sets Xtrain and Ytrain are non-overlapping (they are
a random sample from ZINC-250K split by the median). Xtest is the set of 800 molecules from
ZINC-250K with the lowest values of penalized logP.
Figure 4: Distribution of penalized logP in ZINC-250K and in the sets used in the task of uncon-
strained molecule optimization. Note that the set Xtrain is a random sample from ZINC-250K, and
hence the same distribution is observed for the two sets.
Architecture of the models
All networks are trained using the Adam optimizer34 with learning rate 0.0001. During training
we use batch normalization.35 As the activation function we use leaky-ReLU with α “ 0.1. In
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the structural experiments the models are trained for 100 epochs and in the physiochemical exper-
iments for 300 epochs.
Structural data experiments
• Generators are built of one fully connected residual layer, followed by one dense layer. All
layers contain 56 units.
• Discriminators are built of 6 dense layers of the following sizes: 56, 42, 28, 14, 7, 1 units.
Physiochemical data experiments
• Generators are built of four fully connected residual layers. All layers contain 56 units.
• Discriminators are built of 7 dense layers of the following sizes: 48, 36, 28, 18, 12, 7, 1
units.
Results
Structural transformations
In each structural experiment we test the model’s ability to perform simple transformations of
molecules in both directions X Ñ Y and Y Ñ X . Here, X and Y are non-overlapping sets of
molecules with a specific structural property. We start with experiments on structural properties
because they are easier to interpret and the rules related to transforming between X and Y are well
defined. Hence, the present task should be easier for the model, as compared to the optimization
of complex molecular properties, for which there are no simple rules connecting X and Y .
In Table 2 we show the success rates for the tasks of performing structural transformations of
molecules. The task of changing the number of aromatic rings is more difficult than changing the
presence of halogen moieties. In the former the transition between X (with 2 rings) and Y (with
1 or 3 rings, cf. Fig. 5) is more than a simple addition/removal transformation, as it is in the
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Table 2: Evaluation of models modifying the presence of halogen moieties and the number of
aromatic rings. Success rate is the fraction of times when a desired modification occurs. Non-
identity is the fraction of times when the generated molecule is different from the starting one.
Uniqueness is the fraction of unique molecules in the set of generated molecules.
Halogen moieties Aromatic rings
X Ñ GpXq Y Ñ F pY q X Ñ GpXq Y Ñ F pY q
Success rate 0.6429 0.7161 0.5342 0.4216
Non-identity 0.9345 0.9574 0.9082 0.8899
Uniqueness 0.9952 0.9953 0.9957 0.9954
Figure 5: Distributions of the number of aromatic rings in X and GpXq (left), and Y and F pY q
(right). Identity mappings are not included in the figures.
other case (see Fig. 5 for the distributions of the aromatic rings). This is reflected in the success
rates which are higher for the task of transformations of halogen moieties. In the dataset used
to construct the latent space (ZINC-250K) 64.9 % molecules do not contain any halogen moiety,
whereas the remaining 35.1 % contain one or more halogen moieties. This imbalance might be
the reason for the higher success rate in the task of removing halogen moieties (Y Ñ F pY q).
Molecular similarity and drug-likeness are achieved in all experiments.
To confirm that the generated molecules are close to the starting ones, we show in Figure 6
distributions of their Tanimoto similarities (using Morgan fingerprints). For comparison we also
include distributions of the Tanimoto similarities between the starting molecule and a random
molecule from the ZINC-250K dataset. The high similarities between the generated and the start-
ing molecules show that our procedure is neither a random sampling from the latent space, nor a
13
(a) Halogen moieties (b) Aromatic rings
Figure 6: Density plots of Tanimoto similarities between molecules from Y (and X) and their
corresponding molecules from F pY q (and GpXq). Similarities between molecules from Y (and
X) and random molecules from ZINC-250K are included for comparison. Identity mappings are
not included. The distributions of similarities related to transformations given by G and F show
the same trend.
memorization of the manifold in the latent space with the desired value of the property. In Fig-
ure 7 we visualize the molecules, which after transformation are the most similar to the starting
molecules.
Constrained molecule optimization
As our main task we optimize the desired property under the constraint that the similarity between
the original and the generated molecule is higher than a fixed threshold. This is a more realistic sce-
nario in drug discovery, where the development of new drugs usually starts with known molecules
such as existing drugs.36 Here, we maximize the penalized logP coefficient and use the Tanimoto
similarity with the Morgan fingerprint33 to define the threshold of similarity, simpm,m1q ě δ. We
compare our results with previous similar studies.22,26
In our optimization procedure each molecule (given by the latent space coordinates x) is fed
into the generator to obtain the ‘optimized’ molecule Gpxq. The pair px,Gpxqq defines what we
call an ’optimization path’ in the latent space of JT-VAE. To be able to make a comparison with
the previous research22 we start the procedure from the 800 molecules with the lowest values of
penalized logP in ZINC-250K and then we decode molecules from K “ 80 points along the path
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(a) top: X; bottom: GpXq (b) top: Y ; bottom: F pY q
Figure 7: The most similar molecules with changed number of aromatic rings. In the top row we
show the starting molecules, whereas in the bottom row we show the generated molecules. Below
we provide the Tanimoto similarities between the molecules.
from x to Gpxq in equal steps.
From the resulting set of molecules we report the molecule with the highest penalized logP
score that satisfies the similarity constraint. A modification succeeds if one of the decoded molecules
satisfies the constraint and is distinct from the starting one.
In the task of optimizing penalized logP of drug-like molecules, our method significantly out-
performs the previous results in the mean improvement of the property (see Table 3). It achieves
a comparable mean similarity in the constrained scenario (for δ ą 0). The success rates are com-
parable for δ “ 0, 0.2, whereas for the more stringent constraints (δ “ 0.4, 0.6) our model has
lower success rates (see Table 4). Note that comparably high improvements of penalized logP can
be obtained using reinforcement learning.26 However, the molecules optimized in such a manner
are not drug-like, e.g., they have very low quantitative estimate of drug-likeness score37 even for
δ ą 0. In our method (as well as in JT-VAE) drug-likeness is achieved ‘by construction’ and is an
intrinsic feature of the latent space obtained by training the variational autoencoder on molecules
15
Table 3: Results of the constrained optimization for JT-VAE22, GCPN26 and Mol-CycleGAN.
JT-VAE GCPN Mol-CycleGAN
Delta Improvement Similarity Improvement Similarity Improvement Similarity
0 1.91 ˘ 2.04 0.28 ˘ 0.15 4.20 ˘ 1.28 0.32 ˘ 0.12 8.30 ˘ 1.98 0.16 ˘ 0.09
0.2 1.68 ˘ 1.85 0.33 ˘ 0.13 4.12 ˘ 1.19 0.34 ˘ 0.11 5.79 ˘ 2.35 0.30 ˘ 0.11
0.4 0.84 ˘ 1.45 0.51 ˘ 0.10 2.49 ˘ 1.30 0.47 ˘ 0.08 2.89 ˘ 2.08 0.52 ˘ 0.10
0.6 0.21 ˘ 0.75 0.69 ˘ 0.06 0.79 ˘ 0.63 0.68 ˘ 0.08 1.22 ˘ 1.48 0.69 ˘ 0.07
Table 4: Success rate for constrained optimization for JT-VAE22, GCPN26 and Mol-CycleGAN.
JT-VAE GCPN Mol-CycleGAN
0 97.5% 100.0% 99.75%
0.2 97.1% 100.0% 93.75%
0.4 83.6% 100.0% 58.75%
0.6 46.4% 100.0% 19.25%
from ZINC (which are drug-like).
Molecular paths from constrained optimization experiments
In the following section we show examples of the evolution of the selected molecules for the
constrained optimization experiments. Figures 9-11 show starting and final molecules, together
with all molecules generated along the optimization path and their values of penalized logP.
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Figure 8: Molecules with the highest improvement of the penalized logP for δ ě 0.6. In the top
row we show the starting molecules, whereas in the bottom row we show the optimized molecules.
Upper row numbers indicate Tanimoto similarities between the starting and the final molecule. The
improvement in the score is given below the generated molecules.
Figure 9: Evolution of a selected exemplary molecule during constrained optimization. We only
include the steps along the path where a change in the molecule is introduced. We show values of
penalized logP below the molecules.
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Figure 10: Evolution of a selected exemplary molecule during constrained optimization. We only
include the steps along the path where a change in the molecule is introduced. We show values of
penalized logP below the molecules.
Figure 11: Evolution of a selected exemplary molecule during constrained optimization. We only
include the steps along the path where a change in the molecule is introduced. We show values of
penalized logP below the molecules.
Unconstrained molecule optimization
Our architecture is tailor made for the scenario of constrained molecule optimization. However, as
an additional task, we check what happens when we iteratively use the generator on the molecules
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being optimized. This should lead to diminishing similarity between the starting molecules and
those in consecutive iterations. For the present task the set X needs to be a sample from the entire
ZINC-250K, whereas the set Y is chosen as a sample from the top-20% of molecules with the
highest value of penalized logP. Each molecule is fed into the generator and the corresponding
‘optimized’ molecule’s latent space representation is obtained. The generated latent space repre-
sentation is then treated as the new input for the generator. The process is repeatedK times and the
resulting set of molecules is tGpxq, GpGpxqq, ... }. Here, as in the previous task and as in previous
research22 we start the procedure from the 800 molecules with the lowest values of penalized logP
in ZINC-250K.
The results of our unconstrained molecule optimization are shown in Figure 12. In Figure 12(a)
and (c) we observe that consecutive iterations keep shifting the distribution of the objective (penal-
ized logP) towards higher values. However, the improvement from further iterations is decreasing.
Interestingly, the maximum of the distribution keeps increasing (although in somewhat random
fashion). After 10-20 iterations it reaches very high values of logP observed from molecules
which are not drug-like, similarly to those obtained with RL.26 Both in the case of the RL ap-
proach and in our case, the molecules with the highest penalized logP after many iterations also
become non-drug-like – see Figure 15 for a list of compounds with the maximum values of pe-
nalized logP in the iterative optimization procedure. This lack of drug-likeness is related to the
fact that after performing many iterations, the distribution of coordinates of our set of molecules in
the latent space goes far away from the prior distribution (multivariate normal) used when training
the JT-VAE on ZINC-250K. In Fig. 12(b) we show the evolution of the distribution of Tanimoto
similarities between the starting molecules and those obtained after K “ 1, 2, 5, 10 iterations. We
also show the similarity between the starting molecules and random molecules from ZINC-250K.
We observe that after 10 iterations the similarity between the starting molecules and the optimized
ones is comparable to the similarity of random molecules from ZINC-250K. After around 20 it-
erations the optimized molecules become less similar to the starting ones than random molecules
from ZINC-250K, as the set of optimized molecules is moving further away from the space of
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(a) (b) (c)
Figure 12: Results of iterative procedure of the unconstrained optimization. (a) Distribution of
the penalized logP in the starting set and after K “ 1, 5, 10, 30 iterations. (b) Distribution of the
Tanimoto similarity between the starting moleculesX and random molecules from ZINC-250K, as
well as those generated afterK “ 1, 2, 5, 10 iterations. (c) Plot of the mean value, percentiles (75th
and 90th), and the maximum value of penalized logP as a function of the number of iterations.
drug-like molecules.
Molecular paths from unconstrained optimization experiments
In the following section we show examples of the evolution of selected molecules for the uncon-
strained optimization experiments. Figures 13 and 14 show starting and final molecules, together
with all molecules generated during the iteration over the optimization path and their penalized
logP values.
Figure 13: Evolution of a selected molecule during consecutive iterations of unconstrained opti-
mization. We show values of penalized logP below the molecules.
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Figure 14: Evolution of a selected molecule during consecutive iterations of unconstrained opti-
mization. We show values of penalized logP below the molecules.
Molecules with the highest values of penalized logP
On the Figure 12(c) we plot the maximum value of penalized logP in the set of molecules being
optimized, as a function of number of iterations of for unconstrained molecule optimization. In
Figure 15 we show corresponding molecules for iterations 1-24.
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Figure 15: Molecules with the highest penalized logP in the set being optimized for iterations 1-24
for unconstrained optimization. We show values of penalized logP below the molecules.
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Conclusions
In this work, we introduce Mol-CycleGAN – a new model based on CycleGAN which can be
used for the de novo generation of molecules. The advantage of the proposed model is the ability
to learn transformation rules from the sets of compounds with desired and undesired values of the
considered property. The model operates in the latent space trained by another model – in our work
we use the latent space of JT-VAE. The model can generate molecules with desired properties, as
shown on the example of structural and physicochemical properties. The generated molecules
are close to the starting ones and the degree of similarity can be controlled via a hyperparameter.
In the task of constrained optimization of drug-like molecules our model significantly outperforms
previous results. In the future work we plan to extend the approach to multi-parameter optimization
of molecules using StarGAN.30 It would also be interesting to test the model on cases where a small
structural change leads to a drastic change in the property (e.g. the so-called activity cliffs) which
are hard to model.
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